

Full Length Research paper

Epidemiology of Hepatitis B and C Viruses among HIV-Positive Patients in a Tertiary Health Facility in North Eastern Nigeria

Ballah Akawu Denu^{1*}, Babajide Ajayi², Abubakar Usman Abja³, Abubakar Abdullahi Bukar⁴, Cecilia Akawu⁵, Ernest Ekong⁶ and Mohammed Bashir Alkali⁷

¹Department of Medicine, University of Maiduguri Teaching Hospital, Maiduguri, Borno State Nigeria.

²Department of Immunology University of Maiduguri Teaching Hospital, Maiduguri, Borno State Nigeria.

³Department of Haematology University of Maiduguri Teaching Hospital, Maiduguri, Borno State Nigeria.

⁴Department of Haematology University of Maiduguri Teaching Hospital, Maiduguri, Borno State Nigeria.

⁵Department of Geography University of Maiduguri, Maiduguri, Borno State Nigeria.

⁶AIDS Preventive Initiative in Nigeria (APIN), Nigeria.

⁷Department of Medicine University of Maiduguri Teaching Hospital.

Accepted 06 December, 2012

Co-infection of hepatotropic virus(es), with HIV has been associated with a reduced survival rate, an increased risk of progression to severe liver disease, and an increased risk of hepatotoxicity associated with active antiretroviral therapy. Information regarding prevalence of HBV and HCV co-infection with HIV in Nigeria is limited. This study was designed to determine the seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV), and the impact of co-infection on baseline serum alanine transaminase (ALT), CD4+ T lymphocyte (CD4) count, and plasma HIV-RNA (viral load) in a cohort of HIV-infected Nigerians. Patients confirmed to be positive for HIV infection by Western blot analysis were consecutively recruited into the study from Infectious Disease Clinic, General Out-patient Department and Medical Wards of University of Maiduguri Teaching Hospital, Nigeria. Demographic data and pre-treatment laboratory results (hepatitis B surface antigen (HBsAg), and HCV antibodies (anti-HCV), ALT, CD4 count and viral load) were analysed. A total of 569 HIV-infected patients (male: female ratio, 1:1.4) were consecutively recruited. HBsAg was present in 12.3%; anti-HCV in 0.5% and both markers was not present in any patients. HBsAg prevalence was 12.3% in both male and females, while anti-HCV was detected in 0.8% in males and 0.3% females. HIV-infected patients alone had a higher mean baseline CD4 count compared to those without anti-HCV or HBsAg (181 vs. 117 cells/mm³, respectively; $p = 0.01$). Serum ALT was higher among patients co-infected with HBsAg or anti-HCV than only HIV infected (37 vs. 34 International Units (IU), respectively $p = 0.1$). The high frequency of HBsAg confirms the need for routine screening for these markers in HIV-infected patients in our setting. CD4 count was significantly lower, in patients with prior exposure to hepatitis B or C, while ALT was slightly higher among those positive for HBV or C infection. These findings are pointer to the importance of testing for HBV and HCV in all HIV-infected persons in our setting.

Key words: Hepatitis B, hepatitis C, CD4, HIV.

INTRODUCTION

Chronic viral hepatitis due to hepatitis B virus (HBV) and hepatitis C virus (HCV), as well as infection with human

immunodeficiency virus (HIV) are global public health problems (Alter, 1997; World Health Organization, 1998 Geneva.; Soriano et al., 2004). It has been estimated that about 2 billion people have been infected with hepatitis B virus (HBV) and 350 million have chronic lifelong infection. The prevalence of hepatitis C virus (HCV) is

*Corresponding author. E-mail: d_akawu@yahoo.co.uk.

is also high and it is estimated that about 170 million people are chronically infected while 3 to 4 million people are newly infected every year (http://www.who.int/media/centre/fact-sheet/fs_164/en/ accessed; Merican et al., 2000) A considerable proportion of these patients will progress onto cirrhosis and hepato-cellular carcinoma (Guan et al., 1995; Furusyo et al., 2002).

Worldwide, HIV is responsible for 38.6 million infections as estimated at the end of 2005 (http://www.unaids.org/en/HIV_data/2011GlobalReport/). An estimated one-third of deaths in HIV patients are directly or indirectly related to liver disease. Liver diseases in HIV infected persons can occur due to hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections, chronic alcoholism, hepatic tuberculosis, or due to the effects of antiretroviral therapy (ART) (Kumarasamy et al., 2005; Rathi et al., 1997).

Since the principal routes for HIV transmission are similar to that followed by the hepatotropic viruses, as a consequence, infections with HBV and HCV are expected in HIV infected patients. Co-infections of HBV and HCV with HIV have been associated with reduced survival, increased risk of progression to liver disease and increased risk of hepatotoxicity associated with anti-retroviral therapy. The reported co-infection rates of HBV and HCV in HIV patients have been variable worldwide depending on the geographic regions, risk groups and the type of exposure involved (Alter, 2006; Rockstroh, 2003; Dodig and Tavill, 2001; Tien, 2005; Sungkanuparph et al., 2004). In Europe and USA, HIV-HBV coinfection has been seen in 6 to 14% (Alter, 2006; Rockstroh, 2003) of all patients while HIV-HCV co-infection has been variably reported ranging from 25 to almost 50% (Dodig and Tavill, 2001; Tien, 2005) of these patients. Evidence of exposure to HBV and HCV has been found in 8.7 and 7.8%, respectively, of HIV patients from Thailand (Sungkanuparph et al., 2004) in Southeast Asia. The HIV sero-prevalence in adult Nigerians is estimated at 5%. Viral hepatitis and HIV/AIDS having become so intertwined have constituted a major public health problem in the country. However in spite of this, very little information on viral hepatitis and HIV-co-infection is available. The few reports documented were on HBV-HIV co-infection (Halim et al., 1992; Baba et al., 1998) and HIV /HBV-HCV co-infection in low risk group (Egah et al., 2007). With this background, we set out to determine the prevalence of hepatitis B and C virus infections in HIV-positive patients coming to a tertiary care hospital located in North Eastern Nigeria.

PATIENTS AND METHOD

Study area

The study was conducted in the Department of Medicine, University of Maiduguri Teaching Hospital, Borno State. This is a 500 bedded hospital designated as a Centre of Excellence for infectious

diseases and provides primary, secondary and tertiary services for the North Eastern part of Nigeria. It also caters for the neighbouring countries such as Cameroon, Niger and Chad Republics. Maiduguri, the capital of Borno State, is situated in the North Eastern Nigeria and the largest settlement near the Lake Chad, located on the fringe of the Sahara desert between longitude 11°8'E and 14°4' E and latitudes 10°2'N 13°4'N.

Study participants

Patients confirmed to be positive for HIV infection by Western blot analysis were recruited into the study from Infectious Disease Clinic, General Out-patient Department and Medical Wards of the Hospital from January to December 2010. Informed consent was obtained from each participant with the assurance that all information would be treated with utmost confidentiality. Using a structured, pre-evaluated questionnaire, information was obtained on demographic, clinical manifestation, blood transfusion, sexual behaviour and intravenous drug use. Seroprevalence of HBsAg and Anti-HCV antibodies in apparently, HIV-negative blood donors and those that presented for pre-marital HIV counselling and testing during the same period was also analysed for comparison with the prevalence of hepatitis markers in HIV positive individuals.

Viral diagnosis

Five millilitres of blood were obtained from each participants, the blood were allowed to clot and spun at 1000 xg for 10 min. The serum samples were separated into 2 ml cryorials containers and stored at -20°C until required for testing. The coded samples were anonymously tested using enzyme linked immunosorbent assay kits at a later date for the presence of HBsAg and HCV antibodies (DIA, PRO, Diagnostic Bioprobes Sri, via columella no 20128 milano-Italy).

RESULT

A total of 569 patients were consecutively recruited into the study comprising 235 (41.5%) males and 333 (58.5%) females, with male to female ratio of 1:1.4. The mean age of both sexes was 34.2± 10.1 (14 to 81) years. Male patients were older than females, 37.7 ±10.8 (14 to 81) and 31.8±8.7 (14 to 72) years respectively (p<0.05). The presumed mode of acquiring HIV infection was through heterosexual contact in all the participants.

Data was available for 291 prospective blood donors during the same period. It was presumed that these blood donors represent the general population and they are exposed to similar risk as the general population. There were 249 males and 42 females. The mean age of the donors was 27.8±5.9 (18 to 52).

Prevalence of viral co-infection in HIV positives

The frequency of HBsAg co-infection in HIV+ cohort as reflected in Table 1, was 12.3% (70 in 569) compared to HCV antibody prevalence of 0.5% (3 in 569) with P value < 0.05. Triple infection with both HBsAg and HCV was not seen in any HIV patient.

Table 1. Seroprevalence of HBsAg and anti-HCV antibodies in HIV positive patients.

Variable	HBsAg {n(%)}	HCV {n(%)}
HIV patients (n=569)	70(12.3)	3 (0.5)
Males (n=236)	29(12.3)	2 (0.8)
Females (n=333)	41(12.3)	1 (0.3)
Controls (n= 291)	15 (5.2)	4 (1.4)
Males (n=249)	12 (4.8)	4 (1.6)
Females (n=42)	3(7.1)	0 (0)




Figure 1. Age-related distribution of HBsAg and HCV in HIV positive patients.

The frequency of HBsAg co-infection in blood donors was 5.2% (15 in 291) compared to HCV antibody prevalence of 1.4% (4 in 291) with $P < 0.05$ as depicted in Table 1. Co-infection of infection with both HBsAg and HCV was not seen in any blood donor.

Taking the prevalence's of co-infection in HIV-positive with hepatitis viruses based on gender into accounts, HIV/HBV co-infection was the same in both sexes, it was seen in 29 of 236 (12.3%) males and in 41 of 333 (12.3%) females respectively ($P > 0.05$). HIV co-infection with HCV antibody was seen in 2 of 236 (0.8%) males and in only 1 of 333 (0.3%) females.

The frequency of HBsAg was 4.8% (12 of 249) and 7.1% (3 of 42) in male and female blood donors

respectively; the prevalence of HCVab was 1.6% in males and 0% in females.

Figure 1 shows age related prevalence of HIV co-infection with HBsAg and HCV antibodies. Individuals of age group 10 to 19 years had the highest prevalence of HBsAg (21.4%). This was followed by those of age-group 60 to 69 years (16.7%) and 14.4% in age group 40 to 49 years, while age-group 40 to 49 years has the highest prevalence of HCVab with 0.8% followed by age-groups 20 to 29 and 30 to 39 years with prevalence's of 0.6% and 0.4% respectively.

Table 2 shows immuno-virological parameter of the participants. The mean CD4 count for the HBsAg/HCVab negative was 181 cells/ μ l and it was significantly higher

Table 2. Biochemical, immunological and virological characteristics of patients.

Biochemical characteristics	HIV+	HIV+/HBsAg+/HCVab	p-value
ALT	34.7±12.5	37.3±9.6	0.2
Immunological characteristics			
Mean CD4+T-cells(cells/μl)	181.34 ± 70.8	117±82.23	0.01
Virological characteristics (copies/ml)			
	314561.43±4881.93	617272.38±1045.33	0.03

ALT, CD4 and viral load are expressed in mean values.

than those of the positive (117 cells/μl) ($p < 0.05$). On the contrary, the viral load of HBsAg/HCV negative had significantly lower values than HIV monoinfection ($P < 0.05$). ALT levels did not show any significant difference between the two groups of patients ($P > 0.05$).

DISCUSSION

According to WHO estimates, the global burden of HIV, HCV and HBV is 33.2 million, 170 million and 400 million, respectively. Knowledge of the prevalence and distribution of blood borne viruses and sexually transmitted diseases (STDs) in different parts of the world, and particularly in Africa, is important for the planning of preventive measures and the development of vaccination programmes. More females than males presented for care during the study period, but majority of blood donors were males, all the females were pregnant autologous donors. This gender inequality in presentation for therapy is consistent with the sex distribution documented in the majority of treatment centres particularly in the first decade of antiretroviral therapy. A potential explanation for more females at our centre is that women present for care after positive HIV test on their sick children, death of their husband, or perhaps they are more sensitive to changes in their health and may be socially conditioned to seek and receive assistance for their sickness. This, however, does not translate to more women are infected with HIV in our population, as study in Nigeria actually found that more men were afflicted with HIV/AIDS (Ola et al., 2005).

When asked about the risk factors concerning the viral infections, none of the study subjects reported the history of intravenous drug use or multiple sexual partnership. It is well known that HIV/HBV co-infection is linked most often to sexual intercourse (both heterosexual and men who have sex with men (MSM), followed by IDU, while HIV/HCV co-infection has predominantly been associated with a non-sexual parenteral route of transmission of blood or blood products, particularly IDU (Thomas et al., 1994; Gilson et al., 1997; Kellerman et al., 2003; Rodríguez-Méndez et al., 2000; Sherman et al., 2002). In our study, absence of triple HIV/HBV/HCV may be due to low prevalence of HIV/HCV co-infection as none of the

subjects reported the history of intravenous drug use, neither was needle tract was noticed in their limbs. These results are in agreement with previous reports that HCV is not efficiently transmitted by perinatal or sexual exposure, which are major modes of transmission for HBV and HIV (Kellerman et al., 2003; Rodríguez-Méndez et al., 2000; Sherman et al., 2002). HCV is predominantly found in persons who have had percutaneous exposure to blood products and IDU in particular (Wasley and Alter, 2000). Studies had demonstrated that IDU is the most important factor associated with triple infections with HIV/HBV/HCV in urban HIV-infected populations. It has been reported that the prevalence of HIV-HCV co-infection among IDUs can surpass 90%, highlighting the need for special attention to populations with IDU for screening viral co-infections with HIV and HBV/HCV (Maier and Wu, 2002; Aceijas and Rhodes, 2007).

The co-infection prevalence of 12.3% for HIV and HBV is a pointer to the fact that HBV is a major threat to HIV/AIDS patients in Nigeria, as reported in other parts of the world (Weber et al., 2006) The HBV co-infection rate in this study is similar to prevalence of 11.9% documented in southwestern part of Nigeria, (Otegbayo et al., 2008) but higher than the 9.7% reported in healthy urban population Northern region (Sirisena et al., 2002) but lower than the 25.9% reported in HIV positive in the same region (Uneke et al., 2005). The factors driving these regional differences are unclear. No gender difference in prevalence of HBV was observed in this study. This finding is in contrast with higher prevalence in male, that observed that a high proportion of HBV infections in sub-Saharan Africa is acquired vertically or horizontally (from family members and other children) before the age of 5 years (Davis et al., 1989). Since boys have a predilection for aggressive sports and plays that may result in injury with bleeding, they may be more predisposed to horizontal HBV transmission. Further, societal acceptance of multiple sexual partners for men may contribute to the higher HBV prevalence among HIV-infected men (Zhou et al., 2007).

Anti-HCV co-infection was detected in 0.5% of the patients in this study. In an earlier study, HCV co-infection based on plasma HCV RNA quantification was detected in 8.2% of HIV-infected patients in Northern Nigeria (Agwale et al., 2004). However, cross-study

comparisons may be misleading because of the differences in HCV detection techniques. Quantifiable plasma HCV RNA is present only in patients with active HCV replication. In contrast, anti-HCV can be detected in patients with previous HCV exposure, including those with ongoing HCV replication and those whose immune responses curtailed viral replication. There may be very rare cases of falsely negative anti-HCV in patients with advanced immunosuppression (Mphahlele et al., 2006; Bonacini et al., 2001). In the current study, although the absolute number (n = 3) was relatively small for analysis, the rates of anti-HCV detection were comparable in males (0.8%) and females (0.3%). Although the association between HCV positivity and CD4 count shows conflicting reports (Greub et al., 2000; Anderson et al., 2004; Hershov et al., 2005) It would appear that the immunological status of mono-infection is higher than HBV/HCVab coinfection, as evidenced by the higher CD4 counts in HIV mono-infected than HIV-coinfected with HBV/HCVab. Contrary to observations made Idoko et al in the North-central (Idoko et al., 2009) and Otegbayo et al in South-western part of Nigeria (Otegbayo et al., 2011). The viral load was higher in HBV/HCVab than HIV mono-infected. The mean values of transaminases (ALT) among HBV/HCVab coinfecting patients, was similar to HIV mono-infected in this study.

HCV by itself has not been shown conclusively to be an independent risk factor for more rapid CD4 decline, although it has been associated with increased occurrence of AIDS-defining events (Rockstroh et al., 2005; Stebbing et al., 2005). Studies enrolling a larger number of subjects are needed to elucidate these potential associations further. The limitations of this study are that plasma HCV-RNA was not quantified in patients who had anti-HCV, making it impossible to distinguish active HCV infection from those that have spontaneously cleared the infection.

Conclusion

The high frequency of HBsAg confirms the need for routine screening for these markers in HIV-infected patients in our setting. Significantly lower CD4 and higher viral load, was observed in patients with prior exposure to hepatitis B or C, while ALT was similar among those positive for HBsAg/HCVab and HIV mono-infection. These findings underscore the importance of testing for HBV and HCV in all HIV-infected persons in our setting.

REFERENCES

- Aceijas C, Rhodes T (2007) Global estimates of prevalence of HCV infection among injecting drug users. *Int. J. Drug Policy*, 18: 352–358.
- Aceijas C, Rhodes T (2007) Global estimates of prevalence of HCV infection among injecting drug users. *Int. J. Drug Policy*, 18: 352–358
- Agwale SM, Tanimoto L, Womack C, Odama L, Leung K, Duey D, Negedu-Momoh R, Audu I, Mohammed SB, Inyang U, Graham B, Zeirmann R (2004). Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. *J. Clin. Virol.*, 31 (Suppl 1): S3-6.
- Alter MJ (1997). Epidemiology of hepatitis C. *Hepatology*. 26 (3 Suppl 1): 62S–5S.
- Alter MJ (2006). Epidemiology of viral hepatitis and HIV co-infection. *J. Hepatol.*, 44: S6-S9
- Anderson KB, Guest JL, Rimland D (2004). Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. *Clin. Infect. Dis.*, 39: 1507-13.
- Baba MM, Gashau W, Hassan AW (1998). Detection of hepatitis-B surface antigenaemia in patients with and without the manifestations of AIDS in Maiduguri, Nigeria. *Niger. Postgrad. Med. J.*, 5: 125-8.
- Bonacini M, Lin HJ, Hollinger FB (2001). Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. *J. Acquir. Immune Defic. Syndr.*, 26: 340-344.
- Davis L, Weber D, Lemon S (1989). Horizontal transmission of HBV. *Lancet*, pp. 889-893.
- Dodig M, Tavill AS (2001). Hepatitis C and human immunodeficiency virus coinfections. *J. Clin. Gastroenterol.*, 33: 367-374
- Egah DZ, Banwat EB, Audu E.S, Iya D, Mandong BM, Awele AA, Gomwalk NE (2007). Hepatitis B surface antigen, Hepatitis C and HIV antibody in low-risk blood donor group in Nigeria. *East. Mediterr. Health J.*, 13(4).
- Furusyo N, Nakashima H, Kashiwagi K, et al. (2002) Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. *Am. J. Trop. Med. Hyg.* 67: 151–7.
- Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, McNally T, Kelly GE, Tedder RS, Weller IV (1997). Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. *AIDS*, 11: 597-606
- Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti J-C, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet*. 356: 1800-5.
- Halim NKD, Offor E, Ajayi OI (1992). Epidemiologic study of the seroprevalence of hepatitis-B surface antigen (HBsAg) and HIV-1 in blood donors. *Niger. J. Clin. Pract.*, 2: 42-5.
- Hershov RC, O'Driscoll PT, Handelsman E, Jane P, George H, Leslie S, Ming L, Katherine T, Chen E, Signal Y, Susan P, Katherine D, Adeniyi-Jones S, Thomas DL (2005). Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. *Clin. Infect. Dis.*, 40: 859-860.
- Idoko J, Meloni S, Muazu M, Nimzing N, Badung B, Hawkins C, Sankalé JL, Ekong E, Murphy R, Kanki P, Thio CL (2009), "Impact of Hepatitis B virus Infection on Human Immunodeficiency Virus Response to Antiretroviral Therapy in Nigeria," *Clin. Infect. Dis.*, 49(8): 1268-1273.
- Kellerman SE, Hanson DL, McNaghten AD, Fleming PL (2003). Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. *J. Infect. Dis.*, 188: 571-577.
- Kumarasamy N, Vallabhaneni S, Flanigan TP, Mayer KH, Solomon S (2005). Clinical profile of HIV in India. *Indian J. Med. Res.* 121: 377-394
- Maier I, Wu GY (2002) Hepatitis C and HIV co-infection: a review. *World J. Gastroenterol.* 8: 577–579.
- Merican I, Guan R, Amarapuka D (2000) Chronic hepatitis B virus infection in Asian countries. *J. Gastroenterol. Hepatol.* 15: 1356–61.
- Mphahlele MJ, Lukhwani A, Burnett RJ, Moropeng LM, Ngobeni JM (2006). High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. *J. Clin. Virol.* 35: 14-20.
- Ola SO, Ladipo MM, Otegbayo JA, Odaibo GN, Bamgboye EA, Nwaorgu OG, Shokunbi SW, Olaleye OD (2005). Demographic factors in HIV infected patients seen at UCH, Ibadan, Nigeria. *Afr. J.*

- Med. Med. Sci., 34: 297-301.
- Otegbayo JA, Akingbola TS, Akinyemi JO, Adedapo KS, Odaibo GN, Aken Ova YA, Olaleye DO, Adewole IF, Murphy R, Kanki P (2011). Immunovirological and Biochemical Changes in Nigerian Patients with Hepatitis B Coinfection on Antiretroviral Ther. *World J. AIDS*, 1: 31-36.
- Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, Penugonda S, Adewole IF., Olaleye DO, Murphy R, Kanki P (2008). Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. *Annals Hepatol.*, 7(2): 152-156
- Rathi PM, Amarapurkar DN, Borges NE, Koppikar GV, Kalro RH (1997). Spectrum of liver diseases in HIV infection. *Indian J. Gastroenterol.*, 16: 94-95
- Rockstroh JK (2003). Management of hepatitis B and C in HIV coinfecting patients. *J. Acquir. Immune Defic. Syndr.*, 34(Suppl 1): S59-S65
- Rockstroh JK, Mocroft A, Soriano V (2005). Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J. Infect. Dis.*, 192(6): 992-1002.
- Rodríguez-Méndez ML, González-Quintela A, Aguilera A, Barrio E (2000). Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. *Am. J. Gastroenterol.*, 95: 1316-1322.
- Sherman KE, Rouster SD, Chung RT, Rajicic N (2002). Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clin. Infect. Dis.* 34: 831-837
- Sirisena ND, Njoku MO, Idoko JA, Isamade E, Barau C, Jelpe D, Zamani A, Otawa S (2002). Carriage rate of hepatitis- B surface antigen (HBsAg) in an urban community in Jos Plateau State, Nigeria. *Niger. Postgrad. Med.*, J. 9: 7-10.
- Soriano V, Nunez M, Camino N, Garcia-Samaniego J, Puoti M, Rockstroh J (2004). Treatment of hepatitis C in HIV-infected patients. *Hepatol. Rev.*, 1(2): 59-71.
- Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B (2005). Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS defining events. *Clin. Infect. Dis.*, 41(6): 906-1.
- Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, Thakkestian A (2004). Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. *J. Med. Assoc. Thai*, 87: 1349-1354
- Thomas DL, Cannon RO, Shapiro CN, Hook EW , Alter MJ, Quinn TC (1994). Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. *J. Infect. Dis.*, 169: 990-995
- Tien PC (2005). Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. *Am. J. Gastroenterol.*, 100: 2338-2354
- Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH (2005). Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus- infected patients in Jos, Nigeria. *Mem. Inst. Oswaldo Cruz*, 100: 13-16.
- Wasley A, Alter MJ (2000). Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin. Liver Dis.*, 20: 1-16
- Weber R, Sabin CA, Friis-Moller N, Reiss P, EL-sadr WM, Kirk O, Dabis F, Law MG, Pradier C, Dewits S, Akerlund B, Calvo G, Monforte A, Rickenbach M (2006). Liver-related deaths in persons infected with the human immunodeficiency virus: the D.A.D study. *Arch. Int. Med.* 166(15): 1632-41.
- World Health Organization (1998). The world health report Life in the 21st century: a vision for all: report of the Director-General. Geneva.; Hepatitis-B Fact Sheet No.204. Geneva; Available at: [http://www.who.int/media centre/fact sheet/fs 164/en/ accessed.](http://www.who.int/media centre/fact sheet/fs 164/en/ accessed;); Hepatitis-C Fact Sheet No.164. Geneva; Available at: [http://www.who.int/me-dia centre/fact sheet/fs164en/ accessed.](http://www.who.int/me-dia centre/fact sheet/fs164en/ accessed)
- Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM (2007). Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. *J. Gastroenterol. Hepatol.*, 22(9): 1510-1518.